BioWorld - Tuesday, January 27, 2026

BioWorld Science

Jan. 22, 2018

View Archived Issues

Etanercept biosimilar approved in Japan

Read More

Phase III CORAIL study of Zepsyre does not meet primary endpoint

Read More

MNI-1038 tracer shows promise as PET-based diagnostic for neurodegeneration

Read More

FDA issues complete response letter for CAM-2038 NDA for opioid use disorder

Read More

Phase III HELIOS trial of ASP-0113 misses endpoints

Read More

FDA clears Zealand Pharma to begin phase III trials of dasiglucagon for congenital hyperinsulinism

Read More

Sanofi set to acquire Bioverativ

Read More

Merck & Co. and Idenix describe novel HCV RNA polymerase NS5B inhibitors

Read More

The University of Kentucky patents prostaglandin E synthase inhibitors

Read More

Avacta and OncoSec Medical establish research collaboration

Read More

Novartis to transition Arzerra for CLL to compassionate use programs outside U.S.

Read More

HDAC/histone-lysine N-methyltransferase EHMT2 inhibitors discovered at Georgia State University

Read More

Roche identifies novel anti-influenza compounds

Read More

St Jude Children's Research Hospital patents new anti-CD7 chimeric antigen receptors

Read More

[18F]THK-5351 found useful for brain injury imaging

Read More

New phase I/II trial studies mRNA vaccine BI-1361849 with checkpoint inhibitors in NSCLC

Read More

Phase II study finds sotatercept effective for anemia in lower-risk myelodysplastic syndromes

Read More

FDA grants priority review to Darzalex sBLA in newly diagnosed multiple myeloma

Read More

Akeso Bio studies AK-105 in phase I for advanced solid tumors

Read More

New phase III trial explores use of BAX-111 in pediatric severe hereditary von Willebrand disease

Read More

Dupixent approved in Japan for treatment of atopic dermatitis

Read More

Moderna Therapeutics begins phase I trial of mRNA-1653

Read More